Skip to main content
. 2021 Jul 5;7:86. doi: 10.1038/s41523-021-00292-y

Table 4.

5-year outcome for patients by TILs in primary cancers & germinal center subgroups. A) All HR-negative cases. B) Triple-negative breast cancers.

Number (%) 5-Year iDFS (95% CI) 5-Year dDFS (95% CI) 5-Year OS (95% CI)
(A) All HR-negative cases
Low sTILs (n=86)
 ≤2 GCs 31 (36) 39 (22–55) 39 (22–55) 52 (33–68)
 >2 GCs 55 (64) 73 (59–83) 76 (62–85) 85 (72–92)
High sTILs (n=75)
 ≤2 GCs 9 (12) 100 (−) 100 (−) 100 (−)
 >2 GCs 66 (88) 89 (79–95) 89 (79–95) 94 (84–98)
(B) Triple-negative breast cancers
Low sTILs (n=52)
 ≤2 GCs 16 (31) 25 (8–47) 25 (8–47) 52 (25–74)
 >2 GCs 36 (69) 75 (58–86) 77 (60–88) 82 (66–92)
High sTILs (n=47)
 ≤2 GCs 5 (11) 100 (−) 100 (−) 100 (−)
 >2 GCs 42 (89) 90 (76–96) 90 (76–96) 95 (82–99)